Rchr
J-GLOBAL ID：202001002342247953
Update date: Oct. 27, 2024
Koizume Shiro
コイヅメ シロウ | Koizume Shiro
Contact this researcher
You can send email directly to the researcher.
Affiliation and department：
神奈川県立がんセンター臨床研究所
About 神奈川県立がんセンター臨床研究所
Search "神奈川県立がんセンター臨床研究所"
Detailed information
Research field (1)：
Tumor biology
Research keywords (6)：
lipid metabolism
, tumor microenvironment
, tissue factor
, cancer associated thromboembolism
, hypoxia
, cancer
Research theme for competitive and other funds (7)：
2021 - 2024 卵巣明細胞腺がんにて発現するICAM-1:アポトーシス抑制機構を含む全容の解明
2018 - 2021 Effect of ectopically synthesized coagulation factor VII on venous thromboembolism and malignancy
2017 - 2020 Investigation of pathophysiology and biomarker discovery for prostate cancer in the lipid-deficient hypoxia microenvironment
2014 - 2017 Development of therapeutic strategy of poor prognostic ovarian cancer targeting ischemia-driven expression of ICAM-1
2012 - 2015 Investigation of mechanisms to keep blood vessels patent in hepatocellular carcinoma.
2011 - 2013 Analysis of Sp1-dependent adaptation mechanism of cancer cells to hypoxia for tumor microenvironment-targeted therapy
2009 - 2011 Coagulation factor VII producing tumors and their release of microparticles with coagulation initiating capacity
Show all
Papers (34)：
Yukihide Ota, Mari Uomoto, Shiro Koizume, Shinya Sato, Daisuke Hoshino, Mitsuyo Yoshihara, Yoshiyasu Nakamura, Hiroko Tadokoro, Shohei Myoba, Norihisa Ohtake, et al. Tissue factor pathway inhibitor-2 inhibits integrin β1 activation and focal adhesion formation and suppresses peritoneal ovarian cancer dissemination in mice. Biochemical and biophysical research communications. 2024. 736. 150890-150890
Mari Uomoto, Yukihide Ota, Yukio Suzuki, Asuna Yumori, Hiroto Narimatsu, Shiro Koizume, Shinya Sato, Yoshiyasu Nakamura, Shohei Myoba, Norihisa Ohtake, et al. Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study. BMC Cancer. 2024. 24. 1
田所 弘子, 太田 幸秀, 小井詰 史朗, 佐藤 慎哉, 吉原 光代, 中村 圭靖, 宮城 悦子, 宮城 洋平. がん関連血栓症を含む深部静脈血栓症研究のための下大静脈低灌流による血栓形成マウスモデル(A practical mouse model of thrombosis by hypoperfusion of inferior vena cava for cancer-associated thrombosis research). 日本癌学会総会記事. 2023. 82回. 169-169
Shiro Koizume, Tomohiko Kanayama, Yayoi Kimura, Hisashi Hirano, Tomoko Takahashi, Yukihide Ota, Kaoru Miyazaki, Mitsuyo Yoshihara, Yoshiyasu Nakamura, Tomoyuki Yokose, et al. Cancer cell-derived CD69 induced under lipid and oxygen starvation promotes ovarian cancer progression via fibronectin. Cancer science. 2023
小井詰 史朗, 太田 幸秀, 中村 圭靖, 吉原 光代, 佐藤 慎哉, 田所 弘子, 宮城 悦子, 宮城 洋平. 異所性CD69発現はフィブロネクチン依存的に卵巣明細胞がん細胞の上皮間葉転換を促進させる(Ectopic CD69 expression induces epithelial-mesenchymal transition in ovarian clear cell carcinoma cells via fibronectin). 日本癌学会総会記事. 2022. 81回. P-2288
ｍore...
MISC (17)：
Shiro Koizume, Yukihide Ota, Yoshiyasu Nakamura, Mitsuyo Yoshihara, Shinya Sato, Tomoyuki Yokose, Etsuko Miyagi, Yohei Miyagi. Hypoxia-driven CD69 synthesis enhances ovarian clear cell carcinoma cell survival via integrin-fibronectin interaction. CANCER SCIENCE. 2021. 112. 451-451
Yukihide Ota, Shiro Koizume, Shinya Sato, Yoshiyasu Nakamura, Etsuko Miyagi, Yohei Miyagi. Tissue factor pathway inhibitor-2 (TFPI-2) is a novel immunohistochemical biomarker in ovarian clear cell carcinoma. CANCER SCIENCE. 2021. 112. 770-770
小井詰 史朗, 中村 圭靖, 吉原 光代, 宮城 悦子, 竹中 克也, 宮城 洋平. 転写因子HIF1とSREBP1による共同的GILZ発現増強は卵巣がん細胞の凝固性細胞外小胞生成に重要である(HIF1 and SREBP1 collaborate to induce GILZ expression to produce procoagulant microvesicles in ovarian cancer cells). 日本癌学会総会記事. 2019. 78回. E-1016
竹中 克也, 小森 由香子, 中村 圭靖, 小井詰 史朗, 宮城 洋平. 血清飢餓低酸素環境で発現誘導される酵素とその産物による腫瘍悪性化機序(Cancer progression by an enzyme expression under serum starvation and hypoxia). 日本癌学会総会記事. 2019. 78回. P-1330
竹中 克也, 小森 由香子, 中村 圭靖, 小井詰 史朗, 宮城 洋平. 低酸素で発現誘導されるATP-graspスーパーファミリー酵素(Expression of an ATP-grasp superfamily enzyme under hypoxia). 日本癌学会総会記事. 2018. 77回. 2217-2217
ｍore...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM
